Les tests d'ADNc personnalisés sont destinés à détecter la MRD avant de se récidiver...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-CTDNA-MRD-POST-TREATMENT-BREAST |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-05-18 | actionability review required |
| Maladies | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-CTDNA-MRD-POST-TREATMENT |
|---|---|
| Variante | ctADN: maladie résiduelle minimale — post-néoadjuvant / post-adjuvénile |
| Maladie | DIS-BREAST |
| Niveau ESCAT | IIIA |
| Résumé des faits | Personalized tumor-informed ctDNA assays detect MRD before clinical/ radiographic recurrence in early breast cancer (median lead time 8-18 months). Garcia-Murillas 2019 (TNBC + HR+), Magbanua 2021 (I-SPY2), cTRAK-TN (Turner 2023 — preinvasion intervention with pembrolizumab in TNBC MRD+ failed). c-TRAK-TN-2, ZEST (Bidard 2024 — niraparib in MRD+ HER2-neg) accruing. ESMO Breast Metastatic 2024 notes ctDNA-MRD as emerging risk-stratification, NOT a treatment-escalation trigger outside trials. ESCAT IIIA. |
Notes
STUB pending two-Co-Lead signoff. cTRAK-TN demonstrated that early pembrolizumab in MRD-positive TNBC did NOT prevent recurrence — caution against assuming MRD-guided escalation improves OS in breast. Engine must not surface MRD-positive as a treatment-intensification trigger outside trial enrolment (CHARTER §8.3). No post-treatment breast Indication entity yet ingests ctDNA-MRD status (future IND-BREAST-POST-PRIMARY-CTDNA-MRD-MONITORING). Indications: [] intentional.
Utilisé par
No reverse references found in the YAML corpus.